Gene · 200909
HTR3D: 5-hydroxytryptamine receptor 3D
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. HTR3D: 5-hydroxytryptamine receptor 3D. Genes, record 200909. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/200909
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q70Z44 | 5-hydroxytryptamine receptor 3D | 454 | 0 | Ensembl, GeneID, HGNC |
Source UniProt
Patents9
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 35766 | Q70Z44 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 2011 | Q70Z44 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 2011 | Q70Z44 | Espacenet |
| JP 2025062604 A | 2025-04-14 | 413 | Q70Z44 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 413 | Q70Z44 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 103384 | Q70Z44 | Espacenet |
| JP 2019054813 A | 2019-04-11 | 216201 | Q70Z44 | Espacenet |
| JP 2017121241 A | 2017-07-13 | 216201 | Q70Z44 | Espacenet |
| JP 2015516143 A | 2015-06-08 | 216201 | Q70Z44 | Espacenet |
Drugs15
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| AMISULPRIDE | CHEMBL243712 | Serotonin (5-HT) receptor antagonist | ANTAGONIST | ChEMBL |
| CLOTHIAPINE | CHEMBL304902 | Serotonin 3 (5-HT3) receptor antagonist | ANTAGONIST | ChEMBL |
| DEXFENFLURAMINE | CHEMBL248702 | Serotonin (5-HT) receptor agonist | AGONIST | ChEMBL |
| DEXFENFLURAMINE HYDROCHLORIDE | CHEMBL1887891 | Serotonin (5-HT) receptor agonist | AGONIST | ChEMBL |
| FACINICLINE | CHEMBL2151439 | Serotonin 3 (5-HT3) receptor antagonist | ANTAGONIST | ChEMBL |
| FACINICLINE HYDROCHLORIDE | CHEMBL5095032 | Serotonin 3 (5-HT3) receptor antagonist | ANTAGONIST | ChEMBL |
| MOSAPRIDE | CHEMBL60889 | Serotonin 3 (5-HT3) receptor antagonist | ANTAGONIST | ChEMBL |
| PUMOSETRAG | CHEMBL1643880 | Serotonin 3 (5-HT3) receptor partial agonist | PARTIAL AGONIST | ChEMBL |
| RAMOSETRON | CHEMBL1643895 | Serotonin 3 (5-HT3) receptor antagonist | ANTAGONIST | ChEMBL |
| RAMOSETRON HYDROCHLORIDE | CHEMBL3181841 | Serotonin 3 (5-HT3) receptor antagonist | ANTAGONIST | ChEMBL |
1 to 10 of 15
See all 15 drugsTrials67
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07152184 | AMISULPRIDE | PHASE2 | ClinicalTrials.gov | |
| NCT06887621 | AMISULPRIDE | PHASE2 | ClinicalTrials.gov | |
| NCT06585540 | AMISULPRIDE | PHASE3 | ClinicalTrials.gov | |
| NCT06581302 | AMISULPRIDE | ClinicalTrials.gov | ||
| NCT06166615 | RAMOSETRON | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT06040944 | AMISULPRIDE | ClinicalTrials.gov | ||
| NCT05956600 | AMISULPRIDE | ClinicalTrials.gov | ||
| NCT05347199 | AMISULPRIDE | PHASE1 | ClinicalTrials.gov | |
| NCT04954365 | AMISULPRIDE | ClinicalTrials.gov | ||
| NCT04533724 | AMISULPRIDE | EARLY_PHASE1 | ClinicalTrials.gov |
1 to 10 of 67
See all 67 trialsNIH grants94
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | HTR3D papers | Newest fiscal year |
|---|---|---|---|
| K12DA000167 | Clinician Scientist Training Program (CSTP) | 1 | 2025 |
| P30CA016056 | Roswell Park Cancer Center Support Grant | 1 | 2025 |
| P30CA076292 | Moffitt Cancer Center Support Grant | 1 | 2025 |
| P30DK063491 | Diabetes Research Center (DRC) | 1 | 2025 |
| R01EB023281 | FreeSurfer Development, Maintenance, and Hardening | 1 | 2025 |
| T32CA090314 | Behavioral Oncology Education & Career Development | 1 | 2025 |
| U01CA206110 | Transdisciplinary Team Science in Colorectal Cancer Prognosis: the ColoCare Study | 1 | 2025 |
| U24HG006673 | Systematic Exploration of the Human Interactome IV | 1 | 2025 |
| R01NR018762 | Novel Biomarkers for Cancer-Related Fatigue: Integrating Metabolomics, Genomics and Behaviors | 1 | 2024 |
| R01EY030851 | Integration of clinical measures and theoretical modeling to quantify sectorial specific changes in ocular structure, function, and hemodynamics | 1 | 2023 |
1 to 10 of 94Source NIH's project files
See all 94 nih grantsPapers122
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Predicted conformations of 5-HT3 receptor ion channels are modified by subunit D. | Comput Struct Biotechnol J | 2025 | 40529179 | PubTator, text mining | PubMed |
| Identification of Novel Genomic Variants in COVID-19 Patients Using Whole-Exome Sequencing: Exploring the Plausible Targets of Functional Genomics. | Biochem Genet | 2025 | 39557769 | PubTator, text mining | PubMed |
| Multi-step gene set analysis identified HTR3 family genes involving childhood acute lymphoblastic leukemia susceptibility. | Arch Toxicol | 2025 | 39322821 | PubTator, text mining | PubMed |
| Spatiotemporal expression patterns of anxiety disorder-associated genes. | Transl Psychiatry | 2023 | 38092764 | PubTator, text mining | PubMed |
| A randomized trial evaluating the association between related gene polymorphism and nausea and vomiting induced by cisplatin multi-day chemotherapy. | BMC Med Genomics | 2023 | 37924126 | PubTator, text mining | PubMed |
| 5-HT3 Receptors on Mitochondria Influence Mitochondrial Function. | Int J Mol Sci | 2023 | 37176009 | PubTator, text mining | PubMed |
| Inhibiting 5-hydroxytryptamine receptor 3 alleviates pathological changes of a mouse model of Alzheimer's disease. | Neural Regen Res | 2023 | 36926728 | PubTator, text mining | PubMed |
| Phylogenetic analyses of 5-hydroxytryptamine 3 (5-HT3) receptors in Metazoa. | PLoS One | 2023 | 36857360 | PubTator, text mining | PubMed |
| Association of HTR3B gene polymorphisms with depression and its executive dysfunction: a case-control study. | BMC Psychiatry | 2023 | 36849934 | PubTator, text mining | PubMed |
| Common susceptibility variants of KDR and IGF-1R are associated with poststroke depression in the Chinese population. | Gen Psychiatr | 2023 | 36721715 | PubTator, text mining | PubMed |
1 to 10 of 122
See all 122 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/200909
GET https://conductscience.org/api/genes/v1/200909/drugs